Le Lézard
Classified in: Health, Covid-19 virus
Subject: IMA

Zymo Research Receives CE Mark for New SafeCollecttm At-Home Sample Collection Kits


Self-collection devices designed for ease of use and safety

IRVINE, Calif., Aug. 31, 2021 /CNW/ -- Zymo Research announced today its new line of at-home sample collection kits has received CE marking for sale in the European Union (EU). The SafeCollecttm Sample Collection Kits were designed with consumers' utmost safety in mind for unsupervised self-collection. Currently, the SafeCollecttm technology is available in both swab and saliva collection formats.

The growing number of technology companies and drive-through COVID-19 test sites requiring consumers to collect their own samples has brought scrutiny to the deployment of traditional sample collection devices. To address this need, the scientists and engineers at Zymo Research developed SafeCollecttm, a specially engineered at-home sample collection device that provides user safety and ease of use for consistent sampling. The SafeCollecttm Sample Collection Kits' patented tube features a safety seal that prevents accidental spillage, contact, and/or ingestion of the sample stabilization medium.

SafeCollecttm devices are filled with Zymo Research's proprietary DNA/RNA Shieldtm stabilization solution that preserves DNA and RNA at ambient temperature for at least 30 days. Such preservation is not only economical but also vital when shipping samples where expensive dry ice and other cold shipping methods are not available or permitted.  DNA/RNA Shieldtm was the first 510(k) cleared transport medium for collection, preservation, and inactivation for SARS-CoV-2, which provides an additional layer of protection for those who come into direct contact with samples, including couriers and laboratory personnel.

"At-home testing and self-collection of biological specimens are no longer reserved for niche consumer genetic tests but will be essential to facilitating broad information-based screening and surveillance efforts as well as being a critical aspect of the emerging telehealth market," said Dr. Stanislav Forman of Zymo Research. "The SafeCollecttm Sample Collection Kits were developed to help meet this demand without compromising customer convenience or safety, while also safeguarding collected sample integrity for robust analysis. We wanted to create a new standard in sample collection with the SafeCollecttm product line."

Zymo Research OEM manufactures SafeCollecttm devices for third parties and offers customized filling, labeling, and kitting/packaging. For more information about Zymo Research's SafeCollecttm At-Home Sample Collection Kits, visit their website.

About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific and diagnostics community with state-of-the-art molecular biology tools since 1994. The company's vision "The Beauty of Science is to Make Things Simple" is reflected in all of their products, from epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiome measurements, diagnostic devices, and NGS technologies that are high quality and simple to use. Follow Zymo Research on Facebook, LinkedIn, Twitter, and Instagram.

SOURCE Zymo Research Corp.


These press releases may also interest you

at 05:07
Allied Market Research published a report, titled, "Travel Insurance Market by Insurance Cover (Single-Trip Travel Insurance, Annual Multi-Trip Travel Insurance, and Long-Stay Travel Insurance), Distribution Channel...

at 05:05
Sonida Senior Living, Inc. (the "Company," "we," "our," or "us") , a leading owner-operator and investor in communities and services for seniors, today announced its results for the first quarter ended March 31, 2024. "We achieved strong...

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

9 mai 2024
Star Asia Group is pleased to announce that it has entered into a share transfer agreement with Minacia Co., Ltd. ("Minacia") on April 26, 2024, to acquire 100% of the shares of Minacia. 1? Reason for Share Acquisition Star Asia Group believes that...

9 mai 2024
In the Company's announcement dated May 9, 2024, the 2023 comparative year EBITDA was corrected from $33.2 million to $44.8 million. The complete correct press release follows: Q1 2024 Financial Highlights(1): Revenues of $602.5 millionGross Margin...



News published on and distributed by: